{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ziprasidone+%28Geodon%29&page=2",
    "query": {
      "intervention": "ziprasidone (Geodon)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ziprasidone+%28Geodon%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T15:21:51.502Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01293825",
      "title": "Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Medication Adherence",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "ziprasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2011-01",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-12-30",
      "last_synced_at": "2026-09-27T15:21:51.502Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01293825"
    },
    {
      "nct_id": "NCT01172652",
      "title": "Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Panic Disorder",
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Ziprasidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Palo Alto Health Care System",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 49,
      "start_date": "2010-04",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2025-04-08",
      "last_synced_at": "2026-09-27T15:21:51.502Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • Tampa, Florida • Mason, Ohio",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Mason",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01172652"
    },
    {
      "nct_id": "NCT00515723",
      "title": "Glucose and Lipid Metabolism on Antipsychotic Medication",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Type 2 Diabetes Mellitus",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "risperidone",
          "type": "DRUG"
        },
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "quetiapine",
          "type": "DRUG"
        },
        {
          "name": "ziprasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 96,
      "start_date": "2001-09",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2019-10-02",
      "last_synced_at": "2026-09-27T15:21:51.502Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00515723"
    },
    {
      "nct_id": "NCT00910988",
      "title": "Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hyperglycemia",
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Ziprasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 46,
      "start_date": "2009-02",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-27T15:21:51.502Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00910988"
    },
    {
      "nct_id": "NCT00312494",
      "title": "3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ziprasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 680,
      "start_date": "2006-04",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2021-03-29",
      "last_synced_at": "2026-09-27T15:21:51.502Z",
      "location_count": 66,
      "location_summary": "Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 51 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00312494"
    },
    {
      "nct_id": "NCT01431326",
      "title": "Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adenovirus",
        "Anesthesia",
        "Anxiety",
        "Anxiolysis",
        "Autism",
        "Autistic Disorder",
        "Bacterial Meningitis",
        "Bacterial Septicemia",
        "Benzodiazepine",
        "Bipolar Disorder",
        "Bone and Joint Infections",
        "Central Nervous System Infections",
        "Convulsions",
        "Cytomegalovirus Retinitis",
        "Early-onset Schizophrenia Spectrum Disorders",
        "Epilepsy",
        "General Anesthesia",
        "Gynecologic Infections",
        "Herpes Simplex Virus",
        "Infantile Hemangioma",
        "Infection",
        "Inflammation",
        "Inflammatory Conditions",
        "Intra-abdominal Infections",
        "Lower Respiratory Tract Infections",
        "Migraines",
        "Pain",
        "Pneumonia",
        "Schizophrenia",
        "Sedation",
        "Seizures",
        "Skeletal Muscle Spasms",
        "Skin and Skin-structure Infections",
        "Treatment-resistant Schizophrenia",
        "Urinary Tract Infections",
        "Withdrawal",
        "Sepsis",
        "Gram-negative Infection",
        "Bradycardia",
        "Cardiac Arrest",
        "Cardiac Arrhythmia",
        "Staphylococcal Infections",
        "Nosocomial Pneumonia",
        "Neuromuscular Blockade",
        "Methicillin Resistant Staphylococcus Aureus",
        "Endocarditis",
        "Neutropenia",
        "Headache",
        "Fibrinolytic Bleeding",
        "Pulmonary Arterial Hypertension",
        "CMV Retinitis",
        "Hypertension",
        "Chronic Kidney Diseases",
        "Hyperaldosteronism",
        "Hypokalemia",
        "Heart Failure",
        "Hemophilia",
        "Heavy Menstrual Bleeding",
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel Benjamin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 3520,
      "start_date": "2011-11",
      "completion_date": "2019-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-06",
      "last_synced_at": "2026-09-27T15:21:51.502Z",
      "location_count": 43,
      "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431326"
    },
    {
      "nct_id": "NCT00280566",
      "title": "Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Mania",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ziprasidone Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 584,
      "start_date": "2005-12",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2021-03-25",
      "last_synced_at": "2026-09-27T15:21:51.502Z",
      "location_count": 73,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00280566"
    },
    {
      "nct_id": "NCT00635700",
      "title": "Ziprasidone in the Psychosis Prodrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psychosis Prodrome"
      ],
      "interventions": [
        {
          "name": "ziprasidone",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "16 Years to 40 Years"
      },
      "enrollment_count": 51,
      "start_date": "2008-03",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2023-03-27",
      "last_synced_at": "2026-09-27T15:21:51.502Z",
      "location_count": 10,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00635700"
    },
    {
      "nct_id": "NCT00034801",
      "title": "Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression",
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "ziprasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 378,
      "start_date": "2001-09",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2006-07-19",
      "last_synced_at": "2026-09-27T15:21:51.502Z",
      "location_count": 30,
      "location_summary": "Tuscaloosa, Alabama • Little Rock, Arkansas • Anaheim, California + 27 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00034801"
    },
    {
      "nct_id": "NCT00617058",
      "title": "Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Weight Gain"
      ],
      "interventions": [
        {
          "name": "metformin",
          "type": "DRUG"
        },
        {
          "name": "healthy lifestyle intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 1,
      "start_date": "2007-03",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2012-12-31",
      "last_synced_at": "2026-09-27T15:21:51.502Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00617058"
    }
  ]
}